1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Influenza – Pipeline Review, H1 2013

Influenza – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 459 pages

Influenza – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Influenza - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Influenza. Influenza - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Influenza.
- A review of the Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Influenza pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Influenza.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Influenza pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Influenza - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
Introduction 7
Influenza Overview 8
Therapeutics Development 9
Influenza Therapeutics under Development by Companies 11
Influenza Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 23
Mid Clinical Stage Products 24
Early Clinical Stage Products 25
Discovery and Pre-Clinical Stage Products 26
Influenza Therapeutics - Products under Development by Companies 27
Influenza Therapeutics - Products under Investigation by Universities/Institutes 40
Companies Involved in Influenza Therapeutics Development 42
Influenza - Therapeutics Assessment 143
Drug Profiles 150
Influenza Therapeutics - Drug Profile Updates 376
Influenza Therapeutics - Discontinued Products 420
Influenza Therapeutics - Dormant Products 421
Influenza - Product Development Milestones 429
Appendix 438



List of Tables

Number of Products Under Development for Influenza, H1 2013 29
Products under Development for Influenza - Comparative Analysis, H1 2013 30
Number of Products under Development by Companies, H1 2013 32
Number of Products under Development by Companies, H1 2013 (Contd..1) 33
Number of Products under Development by Companies, H1 2013 (Contd..2) 34
Number of Products under Development by Companies, H1 2013 (Contd..3) 35
Number of Products under Development by Companies, H1 2013 (Contd..4) 36
Number of Products under Development by Companies, H1 2013 (Contd..5) 37
Number of Products under Development by Companies, H1 2013 (Contd..6) 38
Number of Products under Development by Companies, H1 2013 (Contd..7) 39
Number of Products under Development by Companies, H1 2013 (Contd..8) 40
Number of Products under Investigation by Universities/Institutes, H1 2013 42
Comparative Analysis by Late Stage Development, H1 2013 43
Comparative Analysis by Mid Clinical Stage Development, H1 2013 44
Comparative Analysis by Early Clinical Stage Development, H1 2013 45
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 46
Products under Development by Companies, H1 2013 47
Products under Development by Companies, H1 2013 (Contd..1) 48
Products under Development by Companies, H1 2013 (Contd..2) 49
Products under Development by Companies, H1 2013 (Contd..3) 50
Products under Development by Companies, H1 2013 (Contd..4) 51
Products under Development by Companies, H1 2013 (Contd..5) 52
Products under Development by Companies, H1 2013 (Contd..6) 53
Products under Development by Companies, H1 2013 (Contd..7) 54
Products under Development by Companies, H1 2013 (Contd..8) 55
Products under Development by Companies, H1 2013 (Contd..9) 56
Products under Development by Companies, H1 2013 (Contd..10) 57
Products under Development by Companies, H1 2013 (Contd..11) 58
Products under Development by Companies, H1 2013 (Contd..12) 59
Products under Investigation by Universities/Institutes, H1 2013 60
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 61
Baxter International Inc., H1 2013 62
United Therapeutics Corporation, H1 2013 63
Sanofi-Aventis, H1 2013 64
GlaxoSmithKline plc, H1 2013 65
Inovio Biomedical Corporation, H1 2013 66
MedImmune LLC, H1 2013 67
Daiichi Sankyo Company, Ltd, H1 2013 68
Emergent BioSolutions Inc., H1 2013 69
Lentigen Corporation, H1 2013 70
Celltrion, Inc., H1 2013 71
Biotron Limited, H1 2013 72
Novartis AG, H1 2013 73
Aphios Corporation, H1 2013 74
Novavax, Inc., H1 2013 75
Toyama Chemical Co. Ltd, H1 2013 76
Vertex Pharmaceuticals Incorporated, H1 2013 77
Crucell N.V., H1 2013 78
OPKO Health, Inc., H1 2013 79
Zosano Pharma, Inc., H1 2013 80
4SC AG, H1 2013 81
Hemispherx Biopharma, Inc., H1 2013 82
Intercell AG, H1 2013 83
Medicago Inc., H1 2013 84
BioDiem Ltd, H1 2013 85
Mymetics Corporation, H1 2013 86
NanoViricides, Inc., H1 2013 87
Medigen Biotechnology Corp., H1 2013 88
CytoGenix, Inc., H1 2013 89
Amarillo Biosciences, Inc., H1 2013 90
BioCryst Pharmaceuticals, Inc., H1 2013 91
Immuron Limited, H1 2013 92
Green Cross Corporation, H1 2013 93
Cytos Biotechnology AG, H1 2013 94
LG Life Sciences, Ltd, H1 2013 95
Panacea Biotec Limited, H1 2013 96
Functional Genetics, Inc., H1 2013 97
Colby Pharmaceutical Company, H1 2013 98
Iomai Corporation, H1 2013 99
Nutri Pharma ASA, H1 2013 100
LigoCyte Pharmaceuticals, Inc., H1 2013 101
Mucosis B.V., H1 2013 102
Evolva SA, H1 2013 103
Adimmune Corporation, H1 2013 104
Vironova AB, H1 2013 105
ImmunoBiology Limited, H1 2013 106
CureVac GmbH, H1 2013 107
TechnoVax, Inc., H1 2013 108
Okairos, H1 2013 109
Viroblock S.A., H1 2013 110
PDS Biotechnology Corporation, H1 2013 111
Innate Therapeutics Limited, H1 2013 112
Vaxin, Inc., H1 2013 113
EpiVax, Inc., H1 2013 114
Kineta, Inc., H1 2013 115
Indus Biotech Private Limited, H1 2013 116
Romark Laboratories, L.C., H1 2013 117
Chimerix, Inc., H1 2013 118
Adamas Pharmaceuticals, Inc., H1 2013 119
Theraclone Sciences, Inc., H1 2013 120
REPLICor Inc., H1 2013 121
Sinovac Biotech Ltd., H1 2013 122
Wittycell S.A.S., H1 2013 123
Exponential Biotherapies, Inc., H1 2013 124
Immunotope, Inc., H1 2013 125
Microbiotix, Inc., H1 2013 126
NanoBio Corporation, H1 2013 127
Protein Sciences Corporation, H1 2013 128
Shin Nippon Biomedical Laboratories, Ltd., H1 2013 129
ImmunoVaccine Technologies Inc., H1 2013 130
VaxInnate Corporation, H1 2013 131
Immune Design Inc., H1 2013 132
NewLink Genetics Corporation, H1 2013 133
Obio Pharmaceutical Holdings Limited., H1 2013 134
UMN Pharma Inc., H1 2013 135
iBio, Inc., H1 2013 136
PepTcell Limited, H1 2013 137
BiondVax Pharmaceuticals Ltd., H1 2013 138
DynPort Vaccine Company LLC, H1 2013 139
Alios BioPharma, Inc., H1 2013 140
Hawaii Biotech, Inc., H1 2013 141
Variation Biotechnologies, Inc., H1 2013 142
IRX Therapeutics, Inc., H1 2013 143
NexBio, Inc., H1 2013 144
NasVax Ltd., H1 2013 145
ImmuneRegen BioSciences, Inc., H1 2013 146
AIMM Therapeutics B.V., H1 2013 147
Trellis Bioscience, Inc., H1 2013 148
Selecta Biosciences, Inc., H1 2013 149
Cilian AG, H1 2013 150
AmVac AG, H1 2013 151
TSRL, Inc., H1 2013 152
Prosetta Corporation, H1 2013 153
Beech Tree Labs, Inc., H1 2013 154
Vivaldi Biosciences Inc., H1 2013 155
Vaxine Pty Ltd, H1 2013 156
APEPTICO Forschung und Entwicklung GmbH, H1 2013 157
VLP Biotech, Inc., H1 2013 158
AUS Bio Limited, H1 2013 159
AltraVax Inc., H1 2013 160
UNeMed, H1 2013 161
Clarassance, Inc., H1 2013 162
Assessment by Monotherapy Products, H1 2013 163
Assessment by Combination Products, H1 2013 164
Assessment by Stage and Route of Administration, H1 2013 167
Assessment by Stage and Molecule Type, H1 2013 169
Influenza Therapeutics - Drug Profile Updates 396
Influenza Therapeutics - Discontinued Products 440
Influenza Therapeutics - Dormant Products 441
Influenza Therapeutics - Dormant Products (Contd..1) 442
Influenza Therapeutics - Dormant Products (Contd..2) 443
Influenza Therapeutics - Dormant Products (Contd..3) 444
Influenza Therapeutics - Dormant Products (Contd..4) 445
Influenza Therapeutics - Dormant Products (Contd..5) 446
Influenza Therapeutics - Dormant Products (Contd..6) 447
Influenza Therapeutics - Dormant Products (Contd..7) 448



List of Figures

Number of Products under Development for Influenza, H1 2013 29
Products under Development for Influenza - Comparative Analysis, H1 2013 30
Products under Development by Companies, H1 2013 31
Products under Investigation by Universities/Institutes, H1 2013 41
Late Stage Products, H1 2013 43
Mid Clinical Stage Products, H1 2013 44
Early Clinical Stage Products, H1 2013 45
Discovery and Pre-Clinical Stage Products, H1 2013 46
Assessment by Monotherapy Products, H1 2013 163
Assessment by Combination Products, H1 2013 164
Assessment by Route of Administration, H1 2013 165
Assessment by Stage and Route of Administration, H1 2013 166
Assessment by Molecule Type, H1 2013 168
Assessment by Stage and Molecule Type, H1 2013 169

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016’, provides an overview ...

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • October 2016
  • by Global Markets Direct

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections ...

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016’, provides an overview ...


Download Unlimited Documents from Trusted Public Sources

GSK - Company Report, November 2016

  • November 2016
    90 pages
  • Vaccine  

    Infectious Dise...  

  • World  

    United Kingdom  

    Europe  

View report >

GSK - Company Report, November 2016

  • November 2016
    90 pages
  • Vaccine  

    Infectious Dise...  

  • World  

    United Kingdom  

    Europe  

View report >

NanoViricides, Inc. - Quarterly Report, November 2016

  • November 2016
    58 pages
  • Infectious Dise...  

    Influenza  

  • United States  

View report >

Related Market Segments :

Influenza

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.